Jacques Galipeau

Jacques Galipeau, M.D. FRCP(C) obtained his Medical Degree from the University of Montreal and completed specialty training in internal medicine at McGill University. He went on to the Tufts-affiliated New England Medical Center in Boston for three years of subspecialty training in Hematology & Medical Oncology followed by a two-year scientific fellowship in gene Therapy at St-Jude Children’s research hospital in Memphis Tennessee.

Starting in 1997, Dr. Galipeau served as faculty at McGill University before joining Emory University in 2009 as a Professor of Hematology & Oncology and Director of the Emory Personalized Immunotherapy Center. Since September 2016, he has been the Don and Marilyn Anderson Professor of Oncology within the Department of Medicine and UW Carbone Comprehensive Cancer Center at the University of Wisconsin in Madison, and is the inaugural Assistant Dean for Therapeutics Discovery and Development at the University of Wisconsin School of Medicine & Public Health

Dr. Galipeau has initiated and developed an NIH-funded research program in the study and use of mesenchymal stromal cells as an immunotherapy of catastrophic illnesses including cancer and immune disease. He is an internationally recognized expert in translational development of cell therapies and the sponsor of a series of FDA-sanctioned clinical trials examining the use of autologous marrow-derived mesenchymal stromal cells for immune disorders, including Crohn’s disease and graft vs host disease. He has also developed the field of fusion engineered cytokines known as fusokines, as a novel pharmaceutical means of treating immune disorders and cancer.

He is the director of the University of Wisconsin Advanced Cell Therapy Program whose mission is to develop personalized cell therapies for immune and malignant disorders and to promote and deploy first-in-human clinical trials of UW cell therapy innovations to improve outcomes for children and adults.

Dr. Galipeau is the Chair of the ISCT MSC Committee and is a board certified Hematologist with an active clinical practice in consultative benign hematology.